ArticleClinical cardiology2012
Secondary prevention of hyperkalemia with sodium polystyrene sulfonate in cardiac and kidney patients on renin-angiotensin-aldosterone system inhibition therapy.
Article in Clinical cardiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 50 citations in OpenAlex.
- Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes/angiotensin receptor blockers: results from AMETHYST-DN.ESC heart failure · 2018Trial
- Randomized Clinical Trial of Sodium Polystyrene Sulfonate for the Treatment of Mild Hyperkalemia in CKD.Clinical journal of the American Society of Nephrology : CJASN · 2015Trial
- Out of sight, out of mind, but at high risk: incidence, timing and risk factors for hyperkalemia after liver transplant discharge.Frontiers in immunology · 2026Article
- Adverse Gastrointestinal Events With Sodium Polystyrene Sulfonate Use in Patients on Maintenance Hemodialysis: An International Cohort Study.Canadian journal of kidney health and disease · 2023Article
- Cardiorenal Interactions: A Review.CJC open · 2022Review
- Prescription patterns of sodium and calcium polystyrene sulfonate in patients with hyperkalemia and chronic kidney disease receiving RAAS inhibitors.Clinical kidney journal · 2022Article
- Optimizing Therapies in Heart Failure: The Role of Potassium Binders.Biomedicines · 2022Review
- Hyperkalemia: Major but still understudied complication among heart transplant recipients.World journal of transplantation · 2021Review
- Polysulfonate Resins in Hyperkalemia: A Systematic Review.Canadian journal of kidney health and disease · 2020Article
- Hyperkalemia in the Hypertensive Patient.Current cardiology reports · 2018Review
- Evaluation of the tolerability and efficacy of sodium polystyrene sulfonate for long-term management of hyperkalemia in patients with chronic kidney disease.International urology and nephrology · 2017Observational
- Updates in hyperkalemia: Outcomes and therapeutic strategies.Reviews in endocrine & metabolic disorders · 2017Review
- Long-term efficacy of oral calcium polystyrene sulfonate for hyperkalemia in CKD patients.PloS one · 2017Article
- Comparison of activated charcoal and sodium polystyrene sulfonate resin efficiency on reduction of amitriptyline oral absorption in rat as treatments for overdose and toxicities.Iranian journal of basic medical sciences · 2017Article
- Potassium-Binding Agents for the Clinical Management of Hyperkalemia.P & T : a peer-reviewed journal for formulary management · 2016Article
- Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia.Kidney international · 2015Article
- Inhibition of RAS in diabetic nephropathy.International journal of nephrology and renovascular disease · 2015Review
- Management of hyperkalaemia in chronic kidney disease.Nature reviews. Nephrology · 2014Review
- Amitriptyline, clomipramine, and doxepin adsorption onto sodium polystyrene sulfonate.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHyperkalemia, induced by renin-angiotensin-aldosterone system inhibition (RAAS-I) in patients with chronic kidney disease (CKD), or cardiac disease often leads to withdrawal of RAAS-I therapy. Sodium polystyrene sulfonate (SPS) is a potassium-binding resin used for the treatment of hyperkalemia. Recently, concerns about the safety and efficacy of SPS were raised. We report here a follow-up of 14 patients with CKD and heart disease on RAAS-I treatment who were treated with low-dose daily SPS to prevent recurrence of hyperkalemia. HYPOTHESIS: Daily SPS is safe and effective for secondary prevention of hyperkalemia induced by RAAS-I therapy in CKD patients with heart disease.
methodsWe reviewed the medical charts of the patients with CKD (nondialysis patients) and heart disease treated in our CKD clinic from 2005 to 2010 and identified all patients on RAAS-I therapy who were treated with daily SPS (sorbitol-free) after episodes of hyperkalemia. Data on hospitalizations, symptoms that may be attributed to SPS therapy, and electrolyte concentration levels were obtained.
resultsFourteen patients were treated with low-dose SPS therapy for a total of 289 months (median length of follow-up, 14.5 months). None of the patients developed colonic necrosis or life-threatening events that could be attributed to SPS use. Mild hypokalemia was noted in 2 patients and responded to reducing the dose of SPS. No further episodes of hyperkalemia were recorded while patients were on the therapy. SPS was well-tolerated during the follow-up without need for withdrawal or reduction of the dose of RAAS-I therapy by any patients.
conclusionsLow-dose SPS was safe and effective as a secondary preventive measure for hyperkalemia induced by RAAS-I in CKD patients with heart disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.